A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Disability Pride Month: Include, Support, Respect
July is Disability Pride Month which celebrates the different ways people experience disability and promote awareness. The 2026 theme is “The World Wo...
Review: Craft and Connect Pilot Event for Past MND Carers
With thanks to funding from Ms Sharon Green & Mr Marcel Skjald, we designed an event for past MND carers and held a pilot on the Central Coast in...
Top 5 Frequently Asked Questions from June 2026
A diagnosis of Motor Neurone Disease (MND) can raise many questions for the person receiving the diagnosed as well as their family, friends and suppor...
Recordings available: MND Special Interest Group Workshop 2026
We welcomed over 130 members of the MND community to the MND Special Interest Group Workshop on 19 June 2026 in Sydney. Recordings of the main present...